Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

Conditions: Diabetic Nephropathies; Kidney Failure, Chronic; Diabetes Mellitus Type 1; Heart Failure
Interventions: Drug: Sotagliflozin; Drug: Placebo
Sponsors: Alessandro Doria; Juvenile Diabetes Research Foundation; Canadian Institutes of Health Research (CIHR); The Kidney Foundation of Canada; The Cleveland Clinic; University of Washington; University of Michigan; University of Minnesota; University of Colorado, Denver; Northwestern University; Washington University School of Medicine; State University of New York – Upstate Medical University; Providence Medical Research Center; Stanford University; Montefiore Medical Center; University of Toronto; University Health Network, Toronto; University of Calgary; University of Alberta; University of British Columbia; Institut de Recherches Cliniques de Montreal; LMC Diabetes & Endocrinology Ltd.; Joslin Diabetes Center; Lexicon Pharmaceuticals; DexCom, Inc.
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 23, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments